LT4430B - Eye drops - Google Patents
Eye drops Download PDFInfo
- Publication number
- LT4430B LT4430B LT97-015A LT97015A LT4430B LT 4430 B LT4430 B LT 4430B LT 97015 A LT97015 A LT 97015A LT 4430 B LT4430 B LT 4430B
- Authority
- LT
- Lithuania
- Prior art keywords
- eye drops
- solution
- water
- dextran
- preservative
- Prior art date
Links
- 239000003889 eye drop Substances 0.000 title claims abstract description 16
- 229940012356 eye drops Drugs 0.000 title claims abstract description 16
- 239000000243 solution Substances 0.000 claims abstract description 15
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims abstract description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000003755 preservative agent Substances 0.000 claims abstract description 6
- 230000002335 preservative effect Effects 0.000 claims abstract description 6
- 229910021538 borax Inorganic materials 0.000 claims abstract description 5
- UQGFMSUEHSUPRD-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound [Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 UQGFMSUEHSUPRD-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000011780 sodium chloride Substances 0.000 claims abstract description 5
- 239000004328 sodium tetraborate Substances 0.000 claims abstract description 5
- 235000010339 sodium tetraborate Nutrition 0.000 claims abstract description 5
- 150000004676 glycans Chemical class 0.000 claims abstract description 4
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 4
- 239000005017 polysaccharide Substances 0.000 claims abstract description 4
- 229920002307 Dextran Polymers 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- -1 boric acid sodium tetraborate sodium chloride methylparaben Chemical compound 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 abstract description 2
- 229920001353 Dextrin Polymers 0.000 abstract 1
- 239000004375 Dextrin Substances 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000011149 active material Substances 0.000 abstract 1
- 229910052796 boron Inorganic materials 0.000 abstract 1
- 235000019425 dextrin Nutrition 0.000 abstract 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 4
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 4
- 229960002216 methylparaben Drugs 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 3
- 206010013774 Dry eye Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 3
- 239000004327 boric acid Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 125000002353 D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229960001803 cetirizine Drugs 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229960004342 cetirizine hydrochloride Drugs 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- RDQFKNPNVMUGDT-UHFFFAOYSA-L disodium;acetate;hydroxide Chemical compound [OH-].[Na+].[Na+].CC([O-])=O RDQFKNPNVMUGDT-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- QMYDVDBERNLWKB-UHFFFAOYSA-N propane-1,2-diol;hydrate Chemical compound O.CC(O)CO QMYDVDBERNLWKB-UHFFFAOYSA-N 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Šis išradimas yra apie akių lašus,tiksliau,apie vaistų kompoziciją akims,rekomenduojamą akies ragenos apsaugai nuo išorinio poveikio esant vokų deformacijai,po akių vokų plastinių operacijų,epitelizacijos pagerinimui nuo erozijos ir ragenos trofinių pakitimų,gydant akių sausumo sindromą, ragenos uždegimus ir pan.The present invention relates to eye drops, more particularly to a composition for eye care recommended for the protection of the cornea from external effects in the case of eyelid deformation, after eyelid plastic surgery, for improving epithelialization against erosion and corneal trophic lesions, for treating dry eye syndrome, corneal inflammation.
Yra žinomi akių lašai - 0,5% oksietilceliuliozės vandeninis tirpalas (Lakrimol, Lenki jos firmos POLFA katalogas), 1,4% polivinilo alkoholio ir 1,5% metilceliuliozės vandeninis tirpalas (Suomijos firmos STAR katalogas) ir kiti,kurių veiklioji dalis -tai įvairūs celiuliozės dariniai.Eye drops are known - aqueous 0.5% oxyethyl cellulose solution (Lakrimol, POLFA catalog of Polish company), 1.4% polyvinyl alcohol and 1.5% aqueous solution of methyl cellulose (STAR catalog of Finland) and others, the active ingredient of which is various cellulose derivatives.
Artimiausias žinomas techninis sprendimas -antialerginė kompozicija akims ir nosies ertmei,paskelbta Lietuvos patente LT 3344B, kurios veiklioji dalis yra /2-/4-/4-(chlorf enil) fenilmetiy - 1- piperaziniį/etoksi/acto rūgštis (cetirizinas) ar šio junginio druska ir dar gali būti ciklodekstrino junginys,paviršiaus aktyvioji medžiaga ir/ar vandenyje tirpus polimeras. Išradimo aprašyme yra aštuonių kompozicijų pavyzdžiai. Prototipu parinkta antialerginė kompozicija pagal 5 pavyzdį, kurią sudaro (masės dalimis): veiklioji dalis cetirizino hidrochloridas konservantas metilparabenas konservantas propilparabenas paviršiaus aktyvioji medžiaga alfa- ciklodekstrinas stabilizatorius polivinilo alkoholis buferini? tirpalas natrio acetatas natrio hidroksidas iki tirpus poliolis propileno glikolis vanduo ikiThe closest known technical solution is an anti-allergic composition for the eyes and nasal cavity, disclosed in Lithuanian Patent LT 3344B, the active ingredient of which is / 2- / 4- / 4- (chlorophenyl) phenylmethyl-1-piperazine / ethoxy / acetic acid (cetirizine). the salt of the compound and may also be a cyclodextrin compound, a surfactant and / or a water-soluble polymer. The present invention includes examples of eight compositions. Prototype selected antiallergic composition according to Example 5, comprising (by weight) : active ingredient cetirizine hydrochloride preservative methylparaben preservative propylparaben surfactant alpha-cyclodextrin stabilizer polyvinyl alcohol buffer? solution sodium acetate sodium hydroxide to soluble polyol propylene glycol water to
- 0,3- 0.3
- 0,2- 0.2
- 0,1- 0.1
- 0,8 - 0,2- 0.8 - 0.2
0,1 pH 7 - 2,0 IOO gramų.0.1 pH 7 - 2.0 IOO grams.
Veikliosios kompozicijos dalies cetirizino sintezė aprašyta Lietuvos patente LT 2553 (SU 1310397).Tai gana sudėtingas sintetinis junginys,todėl tokio junginio ir vaistų gamyba yra brangi.The synthesis of the active ingredient cetirizine is described in Lithuanian Patent LT 2553 (SU 1310397).
Išradimo uždavinys - sukurti akių lašus,taip vadinamą dirbtinę ašarą,rekomenduojamus akies ragenos apsaugai nuo išorinio poveikio,esant vokų deformacijai,gydant akių sausumo sindromą ir pan.Be to ,šie lašai turi būti tinkami naudoz ti profilaktiškai (dirbant dulkėtose patalpose,akims,kurios jautrios saulės šviesai,pagyvenusiems žmonėms sausose gyvenamose patalpose).SUMMARY OF THE INVENTION - The eye drops to create the so-called artificial tears recommended by the cornea protection against external influences at envelopes bending stiffness in treating dry eye syndrome and pan.Be, these drops used must be suitable for the prevention z (working dust, eyes, which are sensitive to sunlight in the elderly in dry living quarters).
Šis uždavinys pasiekiamas, kai akių lašuose veiklioji sudėtinė dalis yra polisacharidas dekstranas (Cg HIOOg ^n*This object is achieved when the active ingredient in the eye drops is a polysaccharide dextran (Cg H IO Og ^ n *
Jis gaminamas kultivuojant mikroorganizmus sacharozės tirpale. Dekstraną sudaro 06-1,6 jungtimis susieti D-gliukozės liekanos. Jame gali būti ir makromolekulių,kuriose D-gliukozės liekanos susijungę oC-1,4 ; o(,-l, 3 aroC-1,2 jungtimis.Dekstrano molekulinė masė yra nuo 50000 iki 70000.Buferinis tirpalas yra vandenyje ištirpinti boro rūgštis,natrio tetraboratas ir natrio chloridas.Šis tirpalas stabilizuoja tirpalo pH,todėl akių lašų tirpalo reakcija yra neutrali (pH nuo 6,2 iki 7,7). Be to, šis buferinis tirpalas pasižymi ir priešuždegiminėmis savybėmis.It is produced by culturing microorganisms in sucrose solution. Dextran consists of D-glucose residues linked by 06-1.6 bonds. It may also contain macromolecules in which the D-glucose moiety is bound to oC-1,4; o (, - 1, 3 aroC-1,2 bonds. The dextran has a molecular weight of 50,000 to 70,000. The buffer solution is boric acid, sodium tetraborate and sodium chloride dissolved in water.This solution stabilizes the pH of the solution so the reaction of the eye drops solution is neutral (pH 6.2 to 7.7) In addition, this buffer also has anti-inflammatory properties.
Patentuojamuose akių lašuose kaip konservantas yra p-hidroksibenzoinės rūgšties metilo esteris - netilparabenas, kurio molekulinė masė yra 152.The patented eye drops contain a methyl ester of p-hydroxybenzoic acid as the preservative, a net weight of 152.
Komponentų santykis akių lašuose masės dalimis yra:The ratio of the components in parts by weight of the eye drops is:
dekstranas boro rūgštis natrio tetraboratas natrio chloridas metilparabenas vanduodextran boric acid sodium tetraborate sodium chloride methylparaben water
5,0 - 6,55.0 - 6.5
1,11-1,12 0,19 - 0,2 0,25 - 0,26 0,08 -0,12 iki 100 g1.11-1.12 0.19 - 0.2 0.25 - 0.26 0.08 -0.12 to 100 g
I-šradimas iliustruojamas pavyzdžiu.The invention is illustrated by way of example.
Paruošiami akių lašai,kuriuose yra (g):Prepare eye drops containing (g):
Dekstranas poligliukinas (SU,Farmakopėjos straipsnis(F.S.)Dextran polyglucin (SU, Pharmacopoeia article (F.S.)
42-2023-83) - 60,0 g, boro rūgštis ( SU, Valstybinė farmakopė ja( V.F.) , X laida, IO straipsnis,46 psi.) - 11,163 g, natrio tetraboratas (SU,V.F.,X,440 str.,453 psi.) - 1,91 g natrio chloridas (SU,F.S.,42 - 2572 -88) - 2,632 g , metilparabenas(nipaginas)(SU,F.S.,42-1460-89) - 1,0 g, vanduo (SU,V.F.,X,74 str.,108 psl.) - iki 1000 g.42-2023-83) - 60.0 g, boric acid (SU, State Pharmacopoeia (VF), Issue X, Article IO, 46 psi.) - 11.163 g, sodium tetraborate (SU, VF, X, Art. 440). , 453 psi.) - 1.91 g of sodium chloride (SU, FS, 42 - 2572 -88) - 2.632 g, methylparaben (nipagin) (SU, FS, 42-1460-89) - 1.0 g, water ( SU, VF, X, Art. 74, p. 108) - up to 1000 g.
Apskaičiuotą sauso poligliukino kiekį atsargiai šildant ir maišant ištirpina vandenyje.Baigiant tirpti įpila natrio chlorido ir atšaldo iki kambario temperatūros,sumaišo su buferiniu ir metilparabeno tirpalais,paruoštą tirpalą filtruoja ir išfasuoja.The calculated amount of dry polyglucin is dissolved in water with gentle heating and stirring.At the end of dissolution, sodium chloride is added and cooled to room temperature, mixed with buffer and methyl paraben solutions, filtered and packed.
Gatavi akių lašai - tai skaidrus,bespalvis ar gelsvas skystis.Ready eye drops are a clear, colorless to yellowish liquid.
Kokybinė tirpalo analizė:Qualitative solution analysis:
Dekstranas.Į 1-2 ml akių lašų įpilama 1-2 ml 0,1 N natrio hidroksido ir 5 ml 10% vario sulfato.Iškrenta ryškiai mėlynos nuosėdos.Dextran: To 1-2 ml of eye drops add 1-2 ml of 0.1 N sodium hydroxide and 5 ml of 10% copper sulphate. A clear blue precipitate is formed.
Boro rūgštis ir natrio tetraboratas.3 ml tirpalo išgarina lėkštelėje.Ant sausų liekanų užlašina 2 lašus koncentruotos sieros rūgšties ir 5 ml etanolio.Uždegus liepsnos kraštas nusidažo žaliai.Paruošia akių lašų ir 10% druskos rūgšties tirpalą,kuriuo suvilgo kurkumo popierėlį ir išdžiovina.Popierius nusidažo rožine spalva.Boric acid and sodium tetraborate.3 ml of the solution evaporates in a dish.On the dry residue, add 2 drops of concentrated sulfuric acid and 5 ml of ethanol.The flame edge turns green when ignited. pink.
Chlorido joną nustato su sidabro nitratu,natrio - liepsnos reakcija.Chloride ion is detected with silver nitrate, sodium - flame reaction.
Tirpalo pH reakcija tikrinama potenciometru (SU,V.F.,XI,113p).The pH reaction of the solution is checked by potentiometer (SU, V.F., XI, 113p).
Kiekybinė analizė:Quantitative analysis:
Dekstrano (poligliukino) kiekis nustatomas poliarimetru (SU,The dextran (polyglucin) content is determined by the polarimeter (SU,
V.F.,XI,30 psl.).V.F., XI, page 30).
Metilparabeno (nipagino) kiekis nustatomas matuojant šviesos sugertų spektrofotometru,kai bangos ilgis yra 256 nm.The methylparaben (nipagin) content is determined by measuring the light absorbed by a spectrophotometer at 256 nm.
Gatavo tirpalo santykinis klampumas 20 0 C temperatūroje matuojamas kapiliariniu Osvaldo viskozimetru ir lyginamas su boratinio buferinio tirpalo klampumu (SU,V.F.,XI,87 psl.). Jis turi būti nuo 2,8 iki 4,0.The relative viscosity of the reconstituted solution at 20 0 C is measured by a capillary Oswald viscometer and compared with the viscosity of the borate buffer (SU, V.F., XI, p. 87). It should be between 2.8 and 4.0.
Patentuojamų akių lašų klinikiniai tyrimai atliktiClinical trials of patented eye drops have been performed
Maskvos Helmholco vardo akių ligų mokslinio tyrimo institute.Stebėjo 87 ligonius.75 sergantiesiems buvo nustatytas II arba III stadijos akių sausumo sindromas.Tiriamų lašų dozes ir gydymo režimą nustatė individualiai (nuo 3 iki 12 kartų per dieną).Vaistų poveikį tyrė analizuojant Meibomo liaukučių išskiriamą sekretą,epitelio,junginės kraujo indų, prekornealinės plėvelės būklę,ašarų susidarymą,regėjimo pagerėjimą ir subjektyvius pojūčius.Stebėjimo trukmė 3-4 mėnesiai .Teigiamą efektą jau po 7 gydymo dienų pajuto 62 iš stebėtų 75 ligonių (5 vyrų ir 70 moterų nuo 27 iki 68 metų). Taip pat buvo tiriami 12 ligonių,kuriems diagnozuota postherpetinė epiteliopatija.Jie vaistus lašino 3-4 kartus per dieną.Per 14-23 dienas nuo gydymo šiais vaistais pradžios visiems stebėtiems ligoniams epiteliopatijos reiškiniai išnyko . Nustatyta , kad pateikti tyrimams akių lašai,kuriuose rasta nuo 5 iki 6,5% poligliukino,kurio molekulinė masė buvo nuo 50000 iki 70000, pH nuo 6,6 iki 7,7; santykinis klampumas nuo 2,8 iki 4,0zbuvo netoksiški,žmogaus organizmas juos įsisavino gerai,o pašalinio poveikio nepastebėta.Moscow Helmholtz Institute for the Study of Ophthalmology.In 87 patients, 75 patients were diagnosed with stage II or III eye dryness syndrome.The doses and treatment regimens of the drops tested were determined individually (3 to 12 times a day). secretion, epithelial, conjunctival blood vessels, pre-corneal membrane status, tear formation, visual improvement and subjective sensation.Observed for 3-4 months. After 7 days of treatment, 62 of 75 patients (5 men and 70 women aged 27 to 70) 68 years). 12 patients with postherpetic epitheliopathy were also studied. They were given three to four times daily dosing. Within 14-23 days of starting treatment with these drugs, all patients observed had resolved epitheliopathy. Eye drops containing 5 to 6.5% of polyglucin with a molecular weight of 50,000 to 70,000, pH 6.6 to 7.7 were found to be present; the relative viscosities from 2.8 to 4.0 z were non-toxic, well absorbed by the human body, and no adverse effects were observed.
Po atliktų klinikinių tyrimų rekomenduotas galiojimo laikas - 2 metai.After clinical trials, the recommended shelf life is 2 years.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LT97-015A LT4430B (en) | 1997-02-05 | 1997-02-05 | Eye drops |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LT97-015A LT4430B (en) | 1997-02-05 | 1997-02-05 | Eye drops |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LT97015A LT97015A (en) | 1998-08-25 |
| LT4430B true LT4430B (en) | 1998-12-28 |
Family
ID=19721808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LT97-015A LT4430B (en) | 1997-02-05 | 1997-02-05 | Eye drops |
Country Status (1)
| Country | Link |
|---|---|
| LT (1) | LT4430B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1310397A1 (en) | 1981-02-06 | 1987-05-15 | Эжен Бальтес, Жан де Ланнои и Людовик Родригез (BE) | 2-/4-(diphenylmethyl)-1-piperazinyl/-acetic acids or their amides,or their nontoxic pharmaceutically acceptable salts showing spasmolytic and antihistaminic activity |
-
1997
- 1997-02-05 LT LT97-015A patent/LT4430B/en not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1310397A1 (en) | 1981-02-06 | 1987-05-15 | Эжен Бальтес, Жан де Ланнои и Людовик Родригез (BE) | 2-/4-(diphenylmethyl)-1-piperazinyl/-acetic acids or their amides,or their nontoxic pharmaceutically acceptable salts showing spasmolytic and antihistaminic activity |
| LT2553B (en) | 1981-02-06 | 1994-02-28 | Ucb Sa | 2- (4-DIFENILMETIL) -1-PIPERAZINIL) -ACTO STYLE AND ITS AMIDES OR NON-TOXIC PHARMACEUTICAL SALTS, RESPIRATORY AND ANTIHISTAMIC ACTIVITY |
Also Published As
| Publication number | Publication date |
|---|---|
| LT97015A (en) | 1998-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI103714B (en) | Gel-forming liquid medium composition | |
| US5876744A (en) | Highly bioadhesive and mucoadhesive compositions containing polyvinyl alcohol, polycarbophil and biopolymer for the treatment of skin conditions and as vehicles for active ingredients | |
| Noreen et al. | Terminalia arjuna gum/alginate in situ gel system with prolonged retention time for ophthalmic drug delivery | |
| US5358706A (en) | Muco-adhesive polymers | |
| JP2569012B2 (en) | New polysaccharide esters and their salts | |
| JP3683595B2 (en) | Cetirizine-containing antiallergic eye drop composition | |
| CA2468771C (en) | Pharmaceutical composition for use in ophthalmology and rhinology | |
| JP6639480B2 (en) | Aqueous ophthalmic solution and method for treating dry eye syndrome | |
| CZ377192A3 (en) | Process of purifying hyaluronic acid and a fraction of a pure hyaluronic acid for ophthalmological use | |
| TW200402B (en) | ||
| JP6888754B2 (en) | Pharmaceutical product that forms a gel in situ | |
| CN102177180A (en) | Alkylated semi-synthetic glycosaminoglycan ethers and methods of making and using the same | |
| LT3873B (en) | Compositions containing deprotonated hyaluronic acid associates and procrss for preparing same | |
| JPH02504163A (en) | cross-linked carboxypolysaccharide | |
| US5645827A (en) | Muco-adhesive polymers | |
| DE69529063T2 (en) | USE OF BIOPOLYMERS TO TREAT DIGESTIVE INJURY INJURIES | |
| CN104814924A (en) | Brinzolamide liposome eye preparation and preparation method thereof | |
| EP0316174A1 (en) | Aqueous preparation of 9-methyl-3-(1H-tetrazol-5-yl)-4H-Pyrido[1,2-a]pyrimidin-4-one potassium salt | |
| US5200180A (en) | Pharmaceutical composition for the treatment of the human eye | |
| Burgalassi et al. | Larch arabinogalactan for dry eye protection and treatment of corneal lesions: investigations in rabbits | |
| EP1912707B1 (en) | Ophthalmic compositions containing mucoadhesive polysaccharides for the promotion of corneal re-epithelization | |
| JP5184726B2 (en) | Glucosamine-containing cataplasm | |
| LT4430B (en) | Eye drops | |
| EP3331497B1 (en) | A lubricant formulation of carbamoylethyl katira and a process for preparation thereof | |
| KR100963611B1 (en) | Eye drop composition containing alginic acid compound and its manufacturing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM9A | Lapsed patents |
Effective date: 20020205 |